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Association of thin basement membrane nephropathy with hyper-
calciuria, hyperuricosuria and nephrolithiasis.
Background. Familial persistent microhematuria with normal
renal function is the most common presentation of thin basement
membrane nephropathy (TBMN). Gross hematuria episodes and
loin pain attacks are other manifestations of the disease. On the
other hand, it has been shown that hypercalciuria (HC) and
hyperuricosuria (HU) can produce both gross or microscopic
non-glomerular hematuria, in addition to their role in renal stone
formation.
Methods. We studied the prevalence of HC, HU and nephroli-
thiasis in a group of 27 biopsy-proven TBMN as well as in 19
non-biopsied first-degree relatives with persistent microhematuria
and 25 first-degree relatives without microhematuria. A group of
27 patients with IgA nephropathy (IgAN) and persistent micro-
hematuria, and another group of 20 healthy subjects without
known renal diseases were selected as control groups.
Results. Ten (37%) patients with TBMN and 8 (42%) relatives
with microhematuria showed HC and/or HU at presentation;
relatives without microhematuria, IgAN patients and normal
controls showed a significantly lower prevalence of HC and HU.
The prevalence of previous nephrolithiasis among TBMN patients
(25%) was significantly higher than in IgAN patients (3%; P ,
0.05). Family history of nephrolithiasis was recorded in 14 (51%)
of the 27 TBMN families, in contrast with 2 of 27 (7%) with IgAN
and 1 of 20 (5%) in normal controls (P , 0.05). The prevalence of
nephrolithiasis, gross hematuria bouts and loin pain episodes
among TBMN patients and microhematuric relatives showing HC
and/or HU at presentation (44%, 44% and 27%, respectively)
were significantly higher than those of TBMN patients and
microhematuric relatives with normal calcium and uric acid
urinary excretions (10%, 7% and 3%, respectively; P , 0.05). At
the end of follow-up (8.8 6 4.1 years in TBMN patients and 9.1 6
4.2 years in relatives with microhematuria), all the cases main-
tained normal renal function.
Conclusions. We found a high prevalence of HC, HU, and
nephrolithiasis among TBMN patients and relatives with micro-
hematuria. Our study also shows a significant relationship be-
tween the presence of HC and/or HU and the prevalence of
nephrolithiasis, gross hematuria bouts and loin pain episodes.
Hypercalciuria (HC) and hyperuricosuria (HU) are im-
portant lithogenic factors [1]. In addition, several studies
have showed that both metabolic disturbances can be
associated with persistent microscopic hematuria in the
absence of radiographically detectable calculi [2–11]. When
urinary calcium and uric acid are reduced by hydrochlo-
rothiazide or allopurinol, respectively, hematuria resolves
in most cases.
We have observed several patients with persistent micro-
hematuria associated with HC and/or HU in whom micro-
hematuria persisted in spite of the treatment of these
metabolic abnormalities. A later renal biopsy established
the diagnosis of thin basement membrane nephropathy
(TBMN) in most of them. These observations prompted us
to review the history of all those patients diagnosed of
TBMN at the Hospital Universitario 12 de Octubre. Our
study shows a high prevalence of HC, HU and nephrolithi-
asis among patients with TBMN and their families. Our
findings also suggest that some clinical manifestations of
the disease, such as episodes of gross hematuria and loin




From 1980 through 1996, 27 patients were diagnosed by
renal biopsy as having TBMN, according to histologic
criteria described below. All of them have been referred to
our Department because of persistent microhematuria. In
most cases, microhematuria had been discovered in routine
analysis and medical checkups by general practitioners. The
patients were initially submitted to the routine study pro-
tocol that we perform in patients with persistent isolated
microhematuria: a complete physical examination, blood
pressure measurement, general serum biochemistry, uri-
nary sediment examination, 24-hour urinary excretions of
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calcium and uric acid, urine cultures, intravenous urogra-
phy and renal ultrasonography. In the last years, phase-
microscopic examination of urine sediment has been in-
cluded in the study protocol. Microhematuria was defined
as the presence of more than five erythrocytes per high-
power field in the urine sediment in at least three consec-
utive determinations during a six-month period. HC was
defined as a urinary calcium excretion of more than 4
mg/kg/24 hr and HU as a uric acid excretion of more than
800 mg/24 hr in men and 750 mg/24 hr in women [1], in at
least three consecutive determinations. In those cases in
which HC or HU were detected, treatment with hydrochlo-
rothiazide (25 to 100 mg/day) or allopurinol (100 to 300
mg/day) was prescribed for two to four months, in order to
rule out a relationship of microhematuria and both HC or
HU.
After the initial study, a percutaneous renal biopsy had
established the diagnosis of TBMN in every case. Thereaf-
ter, TBMN patients have visited yearly in our outpatient
clinic where the same initial protocol was repeated in every
visit, with the exception of radiological studies (renal
echography) that were performed every three to four years.
In those patients showing HC and/or HU throughout
follow-up, forced fluid intake and dietetic measures (low-
salt and low-purine diets) were prescribed. Hydrochlo-
rothiazides and allopurinol were administered only in cases
with severely increased urinary calcium or uric acid that did
not respond to non-pharmacological measures.
For the present study, the case histories were reviewed to
obtain the clinical and analytical data, both at the time of
initial study and renal biopsy and during follow up. In
addition, patients were questioned in detail about previous
episodes of gross hematuria, symptoms of nephrolithiasis
(passage of stones, visible stone fragments in the urine) and
previous attacks of loin pain not associated with nephroli-
thiasis. They were also carefully questioned about familial
history of hematuria, nephrolithiasis, deafness or renal
failure.
All of the 27 patients with TBMN had a familial history
of hematuria. Forty-four first-degree relatives of 24 out of
the 27 biopsy-proven TBMN patients were studied, and all
of them followed the initial study protocol for patients with
microhematuria described above. Nineteen of these rela-
tives showed persistent microhematuria (relatives with mi-
crohematuria). After the completion of the study they were
visited yearly, identically to biopsy-proven TBMN patients,
although a renal biopsy was not performed. The remaining
25 first-degree relatives showed normal urine sediments
(relatives without microhematuria), and they were not
regularly visited after the initial study.
In order to compare the prevalence of HC, HU and
nephrolithiasis among TBMN patients and their relatives
with that of the other glomerular disorders characterized by
persistent microhematuria, we selected a control group of
27 patients with biopsy-proven IgA nephropathy (IgAN),
persistent microhematuria, and matched for age and sex
with the 27 patients with biopsy-proven TBMN. IgAN
patients performed the same initial study protocol as
TBMN patients and relatives. All IgAN patients had nor-
mal renal function and proteinuria lower than 1 g/24 hr.
Finally, another control group of 20 normal subjects with
no known renal diseases were selected, and a general serum
biochemistry, urinary sediment examination and 24-hr uri-
nary excretions of calcium and uric acid were obtained.
The included relatives of biopsy-proven TBMN patients,
as well as IgAN patients and normal controls, were also
carefully questioned about previous episodes of gross he-
maturia, nephrolithiasis, loin pain attacks and family med-
ical history.
Renal biopsies
Renal biopsies were obtained percutaneously and pro-
cessed for light microscopy, immunofluorescence and elec-
tron microscopy. A Hitachi HU 12 A transmission electron
microscope was used. For morphometric analysis, a mini-
mum of five capillary loops were studied. Ten transverse
measures between endothelial and epithelial membranes,
in areas away from the mesangium, were performed on
each loop. Areas with no sharp outlined membranes were
discarded, assuming that they were on no orthogonal
section. A thickness of 264 nm was considered as the cut-off
point for the diagnosis of TBMN [12, 13]. TBMN was
diagnosed when the mean of our measures was under this
point and no images of thickening or splitting of glomerular
basement membrane were observed. In addition, light
microscopy was normal and immunofluorescence negative.
The diagnosis of IgAN was based on the finding of pre-
dominant mesangial granular immunofluorescent deposits
of IgA. Glomerular basement membrane thickness in
TBMN patients was 174 6 59 nm and in IgAN patients
(measured in 19 patients) 297 6 77 nm.
Laboratory methods
Standard autoanalyzer methods were used for measure-
ment of biochemical parameters. Proteinuria was deter-
mined in a 24-hr urine collection using the sulphosalicylic
acid method. Urinary calcium excretion was measured by
absorption spectrophotometry and urinary uric acid by a
uricase enzymatic test.
Statistical analyses
Values are expressed as means 6 SD. Statistical analyses
were performed by the chi-square test, Fisher’s exact test
and Student’s t-test. Differences were considered signifi-
cant when P , 0.05.
RESULTS
Table 1 shows the principal characteristics at presenta-
tion of patients with biopsy-proven TBMN (N 5 27), their
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non-biopsied first-degree relatives with persistent microhe-
maturia (N 5 19), their first-degree relatives without
microhematuria (N 5 25), the group of IgAN patients (N 5
27), and the control group of normal subjects (N 5 20).
There was a female preponderance among TBMN patients
and their relatives with microhematuria, with a female:
male ratio of 2.5. Persistent microhematuria was present in
all TBMN patients and microhematuric relatives. In addi-
tion, 6 (22%) biopsied patients and 4 (21%) relatives with
microhematuria had had several episodes of gross hematu-
ria. Attacks of intermittent loin pain were described by 4
(14%) TBMN patients and 2 (10%) relatives with micro-
hematuria. The majority of these episodes had been uni-
lateral and coincidental with gross hematuria. Seven (25%)
TBMN patients and 4 (21%) microhematuric relatives
reported recurrent passage of renal stones. History of
nephrolithiasis was present in 14 of the 27 affected families
(51%). Persistent HC and/or HU were detected at presen-
tation in 10 (37%) biopsied patients (isolated HC in 2,
isolated HU in 2 and both HC and HU in 6) and in 8 (42%)
relatives with microhematuria (isolated HC in 2, isolated
HU in 2 and both HC and HU in 4). All biopsied patients
and microhematuric relatives with HC and/or HU were
treated with hydrochlorothiazide and/or allopurinol respec-
tively (see Methods). In spite of the normalization of
calcium and uric acid urinary excretions, microhematuria
persisted in every case.
First-degree relatives without microhematuria showed a
prevalence of HC/HU, nephrolithiasis and episodes of
gross hematuria that were significantly fewer than biopsy-
proven TBMN and relatives with microhematuria (Table
1). In comparison with TBMN patients and microhematu-
ric relatives, IgAN patients showed a significantly higher
percentage of cases with gross hematuria episodes. In
contrast, those with previous nephrolithiasis, family history
of nephrolithiasis and the presence of HC and/or HU
showed a significantly lower prevalence among IgAN pa-
tients and normal controls (Table 1).
As shown in Table 2, the prevalence of nephrolithiasis
was significantly higher among those biopsy-proven TBMN
and microhematuric relatives showing HC and/or HU. We
also found a significantly higher prevalence of gross hema-
turia episodes and loin pain attacks among those biopsied
patients and relatives with microhematuria showing these
metabolic abnormalities. There were no significant differ-
ences in the prevalence of nephrolithiasis, gross hematuria
episodes and loin pain attacks between TBMN patients and
microhematuric relatives showing both HC and HU and
those with isolated HC or HU.
Table 1. Clinical characteristics of patients with biopsy-proven thin basement membrane nephropathy (TBMN), first-degree relatives with or























IgAN patients 30 6 11.3 18 Females 27 (100%) 3 (11%) 1 (3%) 17 (62%)ac 1 (3%) 2 (7%)
(N 5 27) (15–55) 9 Males
Normal controls 30.6 6 12.7 12 Females 0 (0%) 1 (5%) 0 (0%) 0 (0%) 0 (0%) 1 (5%)
(N 5 20) (18–59) 8 Males
a P , 0.05 vs. normal controls
b P , 0.05 vs. IgAN patients
c P , 0.05 vs. relatives without microhematuria.
Table 2. Prevalence of nephrolithiasis, episodes of gross hematuria and































3 (10%)a 2 (7%)a 1 (3%)b
a P , 0.01 compared with patients with HC/HU
b P , 0.05 compared with patients with HC/HU
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Phase-microscopic examination of urine sediment was
performed in 6 biopsy-proven TBMN and in 2 relatives
with microhematuria. The percentage of dysmorphic eryth-
rocytes oscillated between 40 to 70% (mean 52 6 19%).
Renal function was normal in every case of TBMN and
their relatives. Proteinuria higher than 0.2 g/24 hr was
detected in 5 (18%) biopsied patients, ranging from 0.5 to
0.9 g/24 hr, and in one relative with microhematuria (0.6
g/24 hr). Two (7%) biopsied patients showed arterial
hypertension. Deafness was not present in any TBMN
patient nor relatives. A family history of renal failure was
recorded only in 2 of the 27 families. The father of a
biopsy-proven TBMN patient was in chronic dialysis be-
cause of documented ischemic nephropathy (bilateral renal
artery stenoses), and the grandfather of another biopsied
case showed chronic renal insufficiency of unknown etiol-
ogy.
Serum levels of calcium (9.2 6 0.5 mg/dl), phosphorus
(3.2 6 0.6 mg/dl), uric acid (4.5 6 0.8 mg/dl), sodium
(139 6 2.9 mEq/liter), potassium (4.2 6 0.4 mEq/liter) and
bicarbonate (24 6 1.4 mEq/liter) were normal in TBMN
patients as well as in their relatives with microhematuria
(9.4 6 0.5 mg/dl, 3.1 6 0.5 mg/dl, 4.3 6 0.5 mg/dl, 138 6 2.8
mEq/liter, 4.1 6 0.4 mEq/liter and 23 6 1.2 mEq/liter,
respectively) and without microhematuria (9.2 6 0.6 mg/dl,
3.2 6 0.7 mg/dl, 4.1 6 0.8 mg/dl, 138 6 3 mEq/liter, 4.1 6
0.5 mEq/liter and 23 6 1.5 mEq/liter, respectively). Values
of these biochemical parameters did not show significant
differences in IgAN patients (9.3 6 0.5 mg/dl, 3.3 6 0.7
mg/dl, 4.8 6 0.9 mg/dl, 137 6 2.7 mEq/liter, 4.5 6 0.6
mEq/liter and 24 6 1.3 mEq/liter, respectively) and normal
controls (9.1 6 0.4 mg/dl, 3.1 6 0.6 mg/dl, 4.3 6 0.4 mg/dl,
139 6 2.7 mEq/liter, 4.1 6 0.8 mEq/liter and 23 6 1.7
mEq/liter, respectively).
The duration of follow up has been 8.8 6 4.1 years in
biopsied TBMN patients and 9.1 6 4.2 years in their
relatives with microhematuria (Table 3). Microhematuria
persisted in all the cases, although some cases showed
normal urine sediments intermittently. The number of
gross hematuria episodes clearly decreased during the
follow-up: only 2 of 6 TBMN patients complaining of this
symptom at presentation showed new episodes throughout
follow-up, and in one of them gross hematuria bouts were
limited to the first year of follow-up. Similarly, only 1 of 4
microhematuric relatives with history of recurrent gross
hematuria had a new episode during her follow-up. One
biopsied TBMN patient and 2 relatives with microhematu-
ria showed several episodes of renal colic with passage of
stones throughout the follow-up. All the biopsied patients
and relatives with microhematuria showing gross hematuria
bouts or recurrent nephrolithiasis during follow-up had HC
and/or HU at presentation, and continued to show a
tendency to these metabolic disturbances in spite of dietetic
measures (low-salt and low-purine diets).
At the end of the follow-up (Table 3), all of the cases
(biopsied patients and relatives with microhematuria)
maintained normal renal function. Proteinuria higher than
0.2 g/24 hr was present in 7 (25%) biopsied patients,
ranging from 0.3 to 3 g/24 hr, and in 2 (10%) microhema-
turic relatives (0.3 to 4.4 g/24 hr). Four (14%) biopsied
patients and 1 (5%) relative with microhematuria devel-
oped arterial hypertension.
DISCUSSION
Thin basement membrane nephropathy (TBMN) is an
inherited disorder characterized by diffuse thinning of the
glomerular basement membrane [13–18]. Persistent micro-
hematuria with normal renal function is the most common
clinical presentation. TBMN seems to account for most
cases of the so-called benign familial hematuria. Although
some studies have reported a female preponderance [14,
15] others have not confirmed this feature [18]. Gross
hematuria episodes punctuating the persistent microhema-
turia and recurrent loin pain attacks are other less common
clinical manifestations of the disease [14, 16, 18, 19].
We found a high prevalence of HC and HU (37%)
among our biopsy-proven TBMN patients. A similar prev-
alence (42%) was found among their first-degree relatives
with persistent microhematuria. The frequency of HC and
HU in normal subjects is about 2 to 4% and 4 to 6%,
respectively [1]. Both HC and HU are known risk factors
for the development of nephrolithiasis. In agreement with
this relationship, we found a remarkable prevalence of
nephrolithiasis among biopsied TBMN patients and their







hematuria Loin pain Proteinuriaa
Arterialb
hypertension
Biopsy-proven 8.8 6 4.1 27 (100%) 1 (3%) 2 (7%) 2 (7%) 7 (25%) 4 (14%)
TBMN
(N 5 27)
(2–17) (0.3–3 g/24 hr)
Relatives with 9.1 6 4.2 19 (100%) 2 (10%) 1 (5%) 1 (5%) 2 (10%) 1 (5%)
microhematuria
(N 5 19)
(2–15) (0.3–4.4 g/24 hr)
a Proteinuria .0.2 g/24 hr at the end of follow-up
b At the end of follow-up
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relatives with microhematuria (25% and 21%, respective-
ly). Furthermore, history of recurrent nephrolithiasis was
recorded in more than a half of the 27 affected families
(Table 1). The prevalence of nephrolithiasis in our country
is 4.1%, similar to that in other developed countries.
Supporting the role of HC and HU in the formation of
renal stones in our patients, we found that biopsied patients
and microhematuric relatives showing HC and/or HU had
a significantly higher prevalence of nephrolithiasis than
those with normal urinary excretions of calcium and uric
acid (Table 2). In comparison with TBMN patients, we
found a significantly lower prevalence of HC, HU and
nephrolithiasis among a control group of patients with
IgAN and another control group of normal subjects with-
out renal diseases. Interestingly, first-degree relatives with
normal urine sediments showed a prevalence of HC and
HU that was significantly lower than biopsy-proven TBMN
patients and relatives with microhematuria (Table 1). Sim-
ilarly, none of the relatives without microhematuria had a
history of nephrolithiasis, gross hematuria or loin pain
episodes.
The association that we have found between TBMN and
HC, HU and the tendency to nephrolithiasis has not been
previously described to our knowledge. In fact, no system-
atic studies of calciuria/uricosuria had been performed in
this disease. Our findings have interesting clinical implica-
tions, because both HC and HU are well recognized causes
of gross or microscopic hematuria in children and adults
[2–11]. The mechanisms through which these urinary met-
abolic disturbances can cause hematuria have not yet been
identified. It is generally thought that persistent HC and/or
HU can induce microcrystals formation that somehow
injure the tubular epithelium and thus produce bleeding.
The non-glomerular source of this HC/HU-related hema-
turia is supported by some studies that have demonstrated
non-dysmorphic erythrocytes in the urine sediment [20].
Treatment of HC/HU with pharmacological (hydrochloro-
tiazide, allopurinol) and dietetic measures is accompanied
by the disappearance of hematuria in most of the patients
[2–11].
By contrast, our findings strongly suggest that the micro-
hematuria of TBMN patients and their relatives with
microhematuria is unrelated to the presence of HC or HU.
The microhematuria persisted throughout follow-up in our
patients with HC/HU despite appropriate treatment of
both disorders, and in those cases in which a phase-
microscopic examination of urine sediment was performed,
a high percentage of dysmorphic erythrocytes was found.
These data point to the glomerular origin of microhema-
turia in all our patients, in agreement with previous studies
that reported a dysmorphic appearance of urine erythro-
cytes in TBMN [14]. Although it has not been demon-
strated, it is likely that the diffuse thinning of glomerular
basement membrane allows the passage of some red cells
to Bowman’s urinary space, resulting in the persistent
microhematuria characteristic of the disease.
On the other hand, our findings suggest that two other
clinical manifestations of TBMN (episodes of gross hema-
turia and loin pain attacks) could be directly related with
the high prevalence of HC, HU and nephrolithiasis. Previ-
ous studies have described recurrent episodes of gross
hematuria in 5 to 25% of TBMN patients [14, 16–18,
21–23]. We observed (Table 2) a significantly higher prev-
alence of gross hematuria episodes among our patients and
their microhematuric relatives showing HC and/or HU.
Also supporting a causal relationship between these clinical
findings, the number of patients presenting bouts of gross
hematuria and the frequency of such episodes significantly
decreased throughout follow-up. It is possible for the
dietetic and pharmacological measures routinely pre-
scribed to our patients with HC/HU to be related to this
disminution of gross hematuria episodes.
Similarly, we have also found a significant relationship
between the presence of HC/HU and the prevalence of loin
pain episodes among our patients. As with gross hematuria
bouts, loin pain episodes decreased during follow-up, coin-
ciding with therapeutic measures against HC and/or HU.
Loin pain attacks have been reported in about 7 to 17% of
TBMN patients [14, 16, 18]. The clinical characteristics of
these episodes appear to be quite variable and vague (uni-
or bilateral, associated or not to gross hematuria episodes).
Interestingly, Hebert et al have recently described several
patients with a clinical picture consistent with loin pain-
hematuria syndrome that in renal biopsies showed TBMN
[19]. According to renal biopsy findings, these authors
hypothesized that gross hematuria might be responsible for
loin pain through the obstruction of renal tubules by red
cells. They also suggested that a large fraction of patients
with loin pain-hematuria syndrome have TBMN. Unfortu-
nately, no information about calcium and uric acid urinary
excretions was provided in their study.
We suggest, based on our findings, that many loin pain
episodes and gross hematuria bouts in TBMN patients
could be explained by the presence of HC and/or HU.
Through microcrystal formation, these metabolic abnor-
malities would damage renal tubules and thus produce a
non-glomerular gross hematuria. Conditions like dehydra-
tion or physical exercise would increase the probability of
such episodes because of urine oversaturation. Loin pain,
in turn, might be the result of tubular obstruction by
erythrocytes or microcrystals itself. Obviously, more clinical
studies are necessary in order to corroborate these hypoth-
eses.
Most studies concerning TBMN have described an ex-
cellent long-term prognosis [13–19]. However, other stud-
ies have reported a worrying incidence of proteinuria,
hypertension and renal failure [22, 23]. After a mean
follow-up longer than eight years for both biopsy-proven
TBMN and relatives with persistent microhematuria, we
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have not found any case with renal function decline.
Nevertheless, 25% of biopsied patients and 10% of their
relatives with microhematuria developed proteinuria; hy-
pertension was present in 14% of biopsied patients and in
5% of relatives with microhematuria at the end of the
follow-up period. These data stress the importance of a
long-term follow-up in patients with TBMN. Our study also
indicates that periodical measurement of calcium and uric
acid urinary excretions should be included in the study of
these patients. When HC or HU are found, appropriate
treatment of these disorders would decrease the tendency
to renal stone formation and, likely, the incidence of new
gross hematuria episodes and loin pain attacks.
TBMN is inherited in an autosomal dominant fashion
[14]. Recently, a mutation in the gene for alpha-4 chain of
type IV collagen has been described in a family with TBMN
[24]. On the other hand, studies on several families with
idiopathic HC and nephrolithiasis have also demonstrated
an autosomal dominant inheritance [1]. Further genetic
investigations could clarify the basis of the association
between the urinary metabolic disturbances and TBMN
that we have found in this study.
Reprint requests to Manuel Praga, M.D., Servicio de Nefrologı´a, Hospital
12 de Octubre, Crta de Andalucı´a Km 5.400, 28041 Madrid, Spain.
APPENDIX
Abbreviations used in this study are: HC, hypercalciuria; HU, hyper-
uricosuria; IgAN, immunoglobulin A nephropathy; TBMN, thin basement
membrane nephropathy.
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